ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Muneretto, C.
Right arrow Articles by Cabrol, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Muneretto, C.
Right arrow Articles by Cabrol, C.

Ann Thorac Surg 1989;47:151-157
© 1989 The Society of Thoracic Surgeons

Articles

Total artificial heart: Survival and complications

C. Muneretto, MD, E. Solis, MD, A. Pavie, MD, Ph. Leger, MD, I. Gandjbakhch, MD, J. Szefner, MD, V. Bors, MD, C. Piazza, MD, A. Cabrol, MD, C. Cabrol, MD*

Department of Cardio-Thoracic Surgery, La Pitié Hospital, Paris, France

* Address reprint requests to Dr Cabrol, Department of Cardio-Thoracic Surgery, La Pitié Hospital 83, Bd de l'Hôpital, Paris, France.

A total artificial heart was implanted in 28 patients as a bridge to transplantation. Mean time of mechanical support was 14.8 ± 10 days. The 70-mL Jarvik-7 was used in 12 patients and the 100-mL Jarvik-7 in the remaining 16. No clinical thromboembolic complications occurred during implantation. There was no postoperative bleeding requiring operation. Both survival and the rate of complications were similar in the two Jarvik-7 groups. Eleven patients underwent successful transplantation, and 1 patient is still on mechanical support. Sepsis and multiple-organ failure were the most important causes of death. All patients receiving the total artificial heart for severe acute rejection after transplantation died of infection. Early implantation of the total artificial heart is advised in younger patients and in older patients with acute cardiac failure. The use of this device should be contraindicated in immunosuppressed patients because of the high risk of infection.




This article has been cited by other articles:


Home page
 J. Thorac. Cardiovasc. Surg.Home page
M. Kondruweit, T. Strecker, T. Seitz, M. Uder, M. Weyand, and R. Tandler
Stenting of the superior vena cava in a patient with a total artificial heart.
J. Thorac. Cardiovasc. Surg., February 1, 2008; 135(2): 455 - 456.
[Full Text] [PDF]

Home page
 CirculationHome page
L. M. Baddour, M. A. Bettmann, A. F. Bolger, A. E. Epstein, P. Ferrieri, M. A. Gerber, M. H. Gewitz, A. K. Jacobs, M. E. Levison, J. W. Newburger, et al.
Nonvalvular Cardiovascular Device-Related Infections
Circulation, October 21, 2003; 108(16): 2015 - 2031.
[Full Text] [PDF]

Home page
 PerfusionHome page
J. R Pepper
Surgery for heart failure: options and outcomes
Perfusion, July 1, 2000; 15(4): 287 - 293.
[PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1989 by The Society of Thoracic Surgeons.